supp.fit

Diosmin: study protocols

18 study groups say how much Diosmin participants took a day. These are the doses the studies gave. They are not a recommendation.

Diosmin: what the research found →

Dose per serving from products

73 products in our catalogue print how much Diosmin a serving holds.

Most common: 500 mg to 1 g, 48% of 73 products.

Dose per servingProducts
2.5 mg to 5 mg
14
5 mg to 10 mg
1
10 mg to 25 mg
2
25 mg to 50 mg
1
50 mg to 100 mg
0
100 mg to 250 mg
8
250 mg to 500 mg
12
500 mg to 1 g
35

Dose per serving from research

18 study groups in 15 studies say how much Diosmin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 61% of 18 study groups.

Daily doseStudy groups
250 mg to 500 mg
5
500 mg to 1 g
11
1 g to 2.5 g
2

Commonly used together

4 of 18 study groups took Diosmin with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Hesperidin
3

18 study groups

Study
Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency
2003 · Daflon 500 mg group · Patients about 65 years old with chronic venous insufficiency and venous leg ulcers
1 g26 weeks82
Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients
1997 · Dios group · Men and women aged 18–85 with venous leg ulcers no larger than 10 cm and no significant arterial disease
900 mg60 days53
Effect of Pycnogenol on the Healing of Venous Ulcers
2017 · Group 2 · Adults with venous ulcers
900 mg90 days15
Venoactive drug treatment for patients with pelvic varicose veins: Results of the single-center, randomized, open-label study (VENOTREAT)
2025 · diosmin group · Women with symptomatic pelvic venous disorder
600 mg60 days50
Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study
2020 · experimental group · Adults with their first femoropopliteal deep vein thrombosis; mean age 57.8 years, 56 men and 34 women across the study
600 mg1 year45
How we can improve patients' comfort after Milligan-Morgan open haemorrhoidectomy
2011 · Diosmin flavonidic fraction group · Adults with grade III or IV acute mixed hemorrhoids undergoing open haemorrhoidectomy
500 mg7 days43
Efficacy of a Low-Dose Diosmin Therapy on Improving Symptoms and Quality of Life in Patients with Chronic Venous Disease: Randomized, Double-Blind, Placebo-Controlled Trial
2021 · µsmin® Plus (diosmin) group · Men and women aged 18–60 with chronic venous disease, CEAP grade C2–C4
450 mg8 weeks37
Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial
2007 · Daflon arm · Women aged 28–35 with chronic pelvic pain and laparoscopically diagnosed pelvic congestion syndrome
1 g26 weeks10
The Effect of Hesperidin and Diosmin Individually or in Combination on Metabolic Profile and Neuropathy among Diabetic Patients with Metabolic Syndrome: A Randomized Controlled Trial
2023 · diosmin · Adults with type 2 diabetes, metabolic syndrome, and diabetic neuropathy
1 g12 weeks—
Efficacy of Diosmin in Reducing Lower-Extremity Swelling and Pain After Total Knee Arthroplasty: A Randomized, Controlled Multicenter Trial
2024 · diosmin group · Patients undergoing total knee arthroplasty; age and sex not specified
1.8 g2 weeks—
[Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"]
1998 · Hemisynthesis diosmin 600 mg, one tablet per day · Non-menopausal women aged 18 years and over with distressing heavy-leg symptoms and no history of venous thrombosis, varicose veins, or venous reflux
600 mg4 weeks—
[Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"]
1998 · Usual tablet formulation of diosmin 300 mg twice a day · Non-menopausal women aged 18 years and over with distressing heavy-leg symptoms and no history of venous thrombosis, varicose veins, or venous reflux
600 mg4 weeks—
Long-term follow-up of oral administration of flavonoids, Centella asiatica and Melilotus, for diabetic cystoid macular edema without macular thickening
2013 · treatment group · Patients with type 2 diabetes and diabetic cystoid macular edema without macular thickening
300 mg3 years35
The Effect of Hesperidin and Diosmin Individually or in Combination on Metabolic Profile and Neuropathy among Diabetic Patients with Metabolic Syndrome: A Randomized Controlled Trial
2023 · combination of hesperidin and diosmin · Adults with type 2 diabetes, metabolic syndrome, and diabetic neuropathy
1 g12 weeks—
Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin
1994 · Daflon 500 mg group · Patients with chronic venous insufficiency of the lower limbs, stabilized for one year; age and sex not reported
900 mg60 days—
HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial
2002 · Daflon (DF) group · Adults with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis; mean age 41.3 years
1.5 g8 weeks44
Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting
2002 · Micronized diosmin · Healthy male volunteers; age not reported
500 mg1 day12
Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting
2002 · Nonmicronized diosmin · Healthy male volunteers; age not reported
500 mg1 day12